Pathophysiological role of Akt and endothelial nitric oxide synthase in cirrhosis

  • Manuel Morales-Ruiz
Conference paper


Due to the fact that nitric oxide (NO) is a component of air pollution, produced in lightning and also a by-product of microbial metabolism, this substance has been the focus of environmental and microbiological research for many years. However the original clues for a biological role of NO came from studies suggesting the implication of this gas as the active component of nitroglycerin1, which has long been used in the treatment of angina pectoris because of its vasoactive properties. In 1980 Furchgott et al. described a labile and diffusible substance produced by endothelial cells responsible for acetylcholine-dependent blood vessel relaxation2. It was not until a few years later when the two discoveries were connected by Palmer et al.3 and Ignarro et al.4. They published the first evidence that the biological activity of NO was indistinguishable from that of endothelium-derived relaxing factor described by Furchgott et al. These first observations awakened great interest among the scientific community, and generated an enormous amount of literature that culminated in 1992 with the nomination of “Molecule of the Year” by Science journal5. In addition, in 1998 the investigators Robert Furchgott, Ferid Murad, and Louis Ignarro were awarded the Nobel Prize for their research on the effects of NO on blood vessels.


Nitric Oxide Portal Hypertension Portal Pressure Bile Duct Ligation Portal Blood Flow 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Arnold WP, Mittal CK, Katsuki S, Murad F. Nitric oxide activates guanylate cyclase and increases guanosine 3′:5′-cyclic mono phosphate levels in various tissue preparations. Proc Natl Acad Sci USA. 1977;74:3203–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Furchgott RF, Zawadzki JY. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327:524–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA. 1987;84:9265–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Culotta E, Koshland DE Jr. NO news is good news. Science. 1992;258:1862–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet. 1991;337:776–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Bosch J, Garcia-Pagan Je. Complications of cirrhosis. I. Portal hypertension. J Hepatol. 2000;32(Suppl. 1):141–56.PubMedCrossRefGoogle Scholar
  8. 8.
    Gupta TK, Toruner M, Chung MK, Groszmann RJ. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology. 1998;28:926–31.PubMedCrossRefGoogle Scholar
  9. 9.
    Rockey DC, Chung JJ. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology. 1998;114:344–51.PubMedCrossRefGoogle Scholar
  10. 10.
    Hendrickson H, Chatterjee S, Cao S, Morales-Ruiz M, Sessa WC, Shah V. Influence of caveolin on constitutively activated recombinant eNOS: insights into eNOS dysfunction in BDL rat liver. Am J Physiol Gastrointest Liver Physiol. 2003;285:G652–60.PubMedGoogle Scholar
  11. 11.
    Shah V, Toruner M, Haddad F et al. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology. 1999;117:1222–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Shah V, Cao S, Hendrickson H, Yao J, Katusic ZS. Regulation of hepatic eNOS by caveolin and calmodulin after bile duct ligation in rats. Am J Physiol Gastrointest Liver Physiol. 2001;280:G1209–16.PubMedGoogle Scholar
  13. 13.
    Yokomori H, Oda M, Ogi M, Sakai K, Ishii H. Enhanced expression of endothelial nitric oxide synthase and ca veolin-1 in human cirrhosis. Liver. 2002;22:150–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Franke TF, Hornik CP, Segev L, Shostak GA, Sugimoto C. PI3K/Akt and apoptosis: size matters. Oncogene. 2003;22:8983–98.PubMedCrossRefGoogle Scholar
  15. 15.
    Lee MJ, Thangada S, Paik JH et al. Akt-mediated phosphorylation of the G protein-coupled receptor EDG-l is required for endothelial cell chemotaxis. Mol Cell. 2001;8:693–704.PubMedCrossRefGoogle Scholar
  16. 16.
    Gratton JP, Morales-Ruiz M, Kureishi Y, Fulton D, Walsh K, Sessa WC. Akt down-regulation of p38 signaling provides a novel mechanism of vascular endothelial growth factor-mediated cytoprotection in endothelial cells. J Biol Chem. 2001;276:30359–65.PubMedCrossRefGoogle Scholar
  17. 17.
    Morales-Ruiz M, Lee MJ, Zollner S et al. Sphingosine 1-phosphate activates Akt, nitric oxide production, and chemotaxis through a Gi protein/phosphoinositide 3-kinase pathway in endothelial cells. J Biol Chem. 2001;276:19672–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Morales-Ruiz M, Fulton D, Sowa G et al. Vascular endothelial growth factor-stimulated actin reorganization and migration of endothelial cells is regulated via the serine/threonine kinase Akt. Circ Res. 2000;86:892–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Toker A, Newton AC, Akt/protein kinase B is regulated by auto phosphorylation at the hypothetical PDK-2 site. J Biol Chem. 2000;275:8271–4.PubMedCrossRefGoogle Scholar
  20. 20.
    Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol. 1998;10:262–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999;399:601–5.PubMedCrossRefGoogle Scholar
  22. 22.
    Fulton D, Gratton JP, McCabe TJ et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature. 1999;399:597–601.PubMedCrossRefGoogle Scholar
  23. 23.
    Luo Z, Fujio Y, Kureishi Y et al. Acute modulation of endothelial Akt/PKB activity alters nitric oxide-dependent vasomotor activity in vivo. J Clin Invest. 2000;106:493–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Scotland RS, Morales-Ruiz M, Chen Y et al. Functional reconstitution of endothelial nitric oxide synthase reveals the importance of serine 1179 in endothelium-dependent vasomotion. Circ Res. 2002;90:904–10.PubMedCrossRefGoogle Scholar
  25. 25.
    Iwakiri Y, Tsai MH, McCabe TJ et al. Phosphorylation of eNOS initiates excessive NO production in early phases of portal hypertension. Am J Physiol Heart Circ Physiol. 2002;282:H2084–90.PubMedGoogle Scholar
  26. 26.
    Morales-Ruiz M, Cejudo-Martin P, Fernandez-Varo G et al. Transduction of the liver with activated Akt normalizes portal pressure in cirrhotic rats. Gastroenterology. 2003;125:522–31.PubMedCrossRefGoogle Scholar
  27. 27.
    Fulton D, Gratton JP, Sessa WC. Post-translational control of endothelial nitric oxide synthase: why isn’t calcium/calmodulin enough? J Pharmacol Exp Ther. 2001;299:818–24.PubMedGoogle Scholar
  28. 28.
    Groszmann RJ. Beta-adrenergic blockers and nitrovasodilators for the treatment of portal hypertension: the good, the bad, the ugly. Gastroenterology. 1997;113:1794–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Martin PY, Gines P, Schrier RW. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med. 1998;339:533–41.PubMedCrossRefGoogle Scholar
  30. 30.
    Shah V. Cellular and molecular basis of portal hypertension. Clin Liver Dis. 2001;5:629–44.PubMedCrossRefGoogle Scholar
  31. 31.
    Fiorucci S, Antonelli E, Morelli O et al. NCX-1000, a NO-releasing derivative of ursode-oxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension. Proc Natl Acad Sci USA. 2001;98:8897–902.PubMedCrossRefGoogle Scholar
  32. 32.
    Loureiro-Silva MR, Cadelina GW, Iwakiri Y, Groszmann RJ. A liver-specific nitric oxide donor improves the intra-hepatic vascular response to both portal blood flow increase and methoxamine in cirrhotic rats. J Hepatol. 2003;39:940–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Yu Q, Shao R, Qian HS, George SE, Rockey DC. Gene transfer of the neuronal NO synthase isoform to cirrhotic rat liver ameliorates portal hypertension. J Clin Invest. 2000;105:741–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Van de CM, Omasta A, Janssens S et al. In vivo gene transfer of endothelial nitric oxide synthase decreases portal pressure in anaesthetised carbon tetrachloride cirrhotic rats. Gut. 2002;51:440–5.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2004

Authors and Affiliations

  • Manuel Morales-Ruiz
    • 1
  1. 1.Hormonal Laboratory, Hospital Clinic, IDIBAPSUniversity of BarcelonaBarcelonaSpain

Personalised recommendations